In Case You Missed It: Three Things we Learned in our Orphan Drugs Webinar
If you missed our recent webinar in which we dived in the orphan drugs landscape, you skipped a fascinating discussion between biopharma journalist Melanie Senior, author of our recent report “Have Orphans Lost Their Sparkle?”, Evaluate analyst Puru Gaur and special guest Stephanie Léouzon, Managing Director, Biopharma Healthcare at Stifel. The good news is that […]
Orphans are Getting Strategic
You may have read the new report we recently published on the orphan drug market. Rare diseases and their therapies are a huge topic to cover so inevitably, we couldn’t cover everything in the report. However, that’s what webinars are for! I’m delighted to be taking part in Evaluate’s upcoming webinar which will explore the […]
Orphan Drug Report 2024: Slowdown a Sign of Success
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the case for why it is essential biopharma reading below. And while I have your attention, you can grab your complimentary copy of Orphan Drug Report […]
In Case You Missed It: Three Things We Learned From Our Orphan Drug Webinar
Missed our webinar on orphan drugs and the impact of the Inflation Reduction Act? Well, you missed a lot but here are a few takeaways to help you catch up. And the full webinar is available on demand. Drugs for orphan indications are a fascinating area of the pharma industry. Our recent report on the […]
It’s All About Impact: Why Orphan Drugs are a Big Deal for Patients and Pipelines
300 million people worldwide are living with a rare disease. The “orphan” drugs created to treat them have been a fast-growing part of the pharma market for years – and their use is often high profile. Every now and then a relative niche of the pharma world hits the mainstream – orphan drugs. It happened […]
Orphan Drugs: About as Niche as a Flat White
To those beyond the world of biopharma, the term “orphan drug” sounds a bit sad, a bit forgotten. But to those involved in the industry, the superior return on investment, supportive regulatory environment and rates of growth mean that these orphans are anything but tragic. We’ve just published our latest report on the state […]
